2017

Wellcome Trust Funded Project in CMS

Strengthening the neuromuscular junction as a new concept for the treatment of congenital myasthenic syndromes and motor neuropathies with synaptic dysfunction

Disruption of the development and maintenance of the neuromuscular junction (NMJ) through mutations in the genes encoding its components or auto-antibodies against its elements lead to congenital myasthenic syndromes (CMS) and acquired myasthenia gravis (MG) respectively. These disorders result in impaired neurotransmission, and fatigable muscle weakness. The phenotypical spectrum of NMJ dysfunction is expanding; several recently identified mutations in presynaptic NMJ proteins have been shown to cause hereditary motor neuropathies, and NMJ abnormalities have been demonstrated in genetic neuropathies. Current treatments for these conditions are limited in that they are mainly symptomatic and limited by systemic side-effects.

Development and maintenance of the NMJ critically depends on the neuronal factor agrin, and the agrin/LRP4/MuSK pathway. The naturally occurring form of agrin is highly insoluble and its activity is counteracted by cleavage by a specific serine protease (neurotrypsin). Neurotune AG, a Swiss biotech company, has developed a modified form of agrin (NT-1654) which is soluble and resistant to specific proteolysis. Through a Pathfinder Award, Professor Lochmüller and colleagues at Newcastle University will test the effect of NT-1654 in mouse models of human CMS and in a mouse model of hereditary motor neuropathy. The team aim to provide evidence that NT-1654 improves neuromuscular transmission in these mouse models and to identify the pharmacokinetic properties and molecular mechanisms of this improvement, thus providing further evidence for its use as a therapeutic reagent in clinical trials (Source: Wellcome Trust Pathfinder Awards).

News

Selected News from the Archive 2008-2016

15 Jan 2014

The NTtotalCAF ELISA is now officially available.

 

22 June 2012

Since its successful launch the NTCAF ELISA assay has been further developed.

The range of Neurotune’s diagnostic assay to stratify sarcopenia patients is now extended to further body fluids beyond serum. Plasma and urine may also be used for the in vitro assessment of the sarcopenia biomarker CAF (C-terminal Agrin Fragment). For more information see the revised factsheet.

 

14 May 2012

The ALS Therapy Development Institute Partners with Neurotune to investigate Potential Treatments for Motor Neuron Desease. Partnership aimed at Neuromuscular Junction Strength against Disease Course.

The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig’s desease).

 

2 March 2012

Neurotune launches the world’s first ELISA based diagnostic assay for C-terminal Agrin Fragments (CAF) in blood.
Neurotune AG, a Swiss biopharmaceutical company, announces the launch of its immunoassay, NTCAF ELISA, the world’s first ELISA based assay for sarcopenia.

 

5 December 2011

Neurotune AG is Coordinator of an Eurostars funded Project entitled “Early Diagnosis and Monitoring of Renal Diseases” (Acronym: KIDNEY).
The scope of the project is the validation of a new and most effective diagnostic biomarker (RCAF) for the early monitoring of chronic kidney disease with a possible application in the prognosis of kidney transplant and in acute kidney injury.

 

14 November 2011

Schlieren (Zurich), Switzerland, 14 November 2011. The FDA has granted Neurotune AG an IND for dimiracetam, the company’s lead compound for treatment of neuropathic pain conditions. Neurotune is planning a pivotal study to demonstrate efficacy of dimiracetam in alleviating neuropathic pain in AIDS patients affected with a treatment related symmetrical painful peripheral neuropathy.

 

23 February 2011

Neurotune receives EU funding for sarcopenia project
Neurotune AG today announced it is leading a consortium of research teams in the DISARCO project, a two-year project focused on developing an immunoassay for the diagnosis of sarcopenia. The consortium has received €720,000 from the European Eurostars Programme to fund the research.

 

12 January 2011

Der BIO-TECHNOPARK® Schlieren-Zürich ist zusammen mit Neurotune, ETH Zürich, Universität Zürich und der Standortförderung des Kantons Zürich Partner im EU-Projekt HealthTIES.

 

16 December 2010

Neurotune wins the third place in the 2010 Eurecan European Venture Contest (EEVC) finals in the category healthcare companies. The finalists were selected by an international jury out of 987 applications from 24 countries.

 

21 October 2010

Neurotune announces positive top-line Phase IIa results for dimiracetam to treat neuropathic pain in HIV patients
Neurotune AG, a Swiss biopharmaceutical company, today announced positive top-line results from its phase IIa, safety and tolerability, study of dimiracetam (NT-11624), its lead compound for treatment-induced neuropathic pain in HIV patients receiving anti-retroviral medication.

 

17 August 2009

Neurotune announces regulatory approval for Phase II Clinical Trial to treat neuropathic pain in HIV patients
Neurotune AG has received MCC ’s (the South African National Regulatory Agency) approval for a Phase II clinical study of Neurotune’s lead compound NT-11624 for neuropathic pain caused by treatment with anti-retroviral medication.

 

15 January 2009

Neurotune successfully completes Phase I Trials with its Lead Compund NT-11624
Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase I for its lead compound NT-11624 developed for treatment of neuropathic and osteoarthritic pain. NT-11624, dimiracetam, is a selective small molecular NMDA-receptor antagonist, which acts on a new site of the receptor.

 

18 September 2008

Neurotune expands its portfolio by acquiring neuropathic pain projects
Neurotune AG announces that the shareholders meeting, held on August 29th 2008, approved of the expansion of its portfolio with two programs in neuropathic pain. The company has reached an agreement with the Italy-based company Brane Discovery Srl. to acquire rights for two programs in neuropathic pain in a combined cash and share transaction.

 

29 July 2008

Neurotune completes next funding round
Neurotune AG announces the closing of the fourth funding round. Another single-digit million Swiss francs will accrue to the company. The company will use the increase in capital to advance the development of its therapeutical approach to treat sarcopenia and along with this the diagnostical methods. Part of the capital will be used to extend a developmental pipeline.

 

19 June 2007

Neurotune AG is honoured on the occasion of the award ceremony „ZKB Pioneer Award TECHNOPARK® 2007“
Neurotune AG was awarded a prize for its activity in the area of developing drugs to treat age-related muscle atrophy – Sarcopenia – and other disorders of the human nervous system on Tuesday evening.